Top Abstract Purchase Related
Home
>
Node
>
Subnode

Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation

Nakagawa, M.

Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92

1993

ISSN/ISBN: 0047-1852
PMID: 7679453
Document Number: 409388
Pathophysiology of DIC varies with underlining diseases but its precipitating factor is accepted to be mainly as an accerelation of blood coagulation. From these back grounds it is indicated that the removal of the original pathogenetic factor is important as the first step of treatment, and at the same time the anticoagulant treatment has been also advised as a fundamental remedy against this disease state. For this purpose, heparin, low molecular weight heparin, heparinoid, or antithrombin III has been used so far on the clinical practice. However their beneficial effects or efficasies have not been established yet. This paper reports the pharmacological properties of these anticoagulants and some data of their clinical evaluations.

Document emailed within 1 workday
Secure & encrypted payments

Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Riabov, G.A.; Pasechnik, I.N.; Emtsov, I.G. 1991: The heparin prophylaxis of gas exchange disorders in disseminated intravascular blood coagulation Terapevticheskii Arkhiv 63(7): 74-77
Jespersen, J. 1981: Acute pancreatitis with disseminated intravascular coagulation treated with heparin and plasma Ugeskrift for Laeger 143(18): 1152-1153
Corrigan, J.J.; Jordan, C.M.; Bennett, B.B. 1973: Disseminated intravascular coagulation in septic shock. Report of three cases not treated with heparin American Journal of Diseases of Children 126(5): 629-632
Castaman, G.; Ruggeri, M.; Girardello, R.; Rodeghiero, F. 1992: An unusually prolonged case of heparin-induced thrombocytopenia and disseminated intravascular coagulation Haematologica 77(2): 174-176
Barkagan, Z.S.; Momot, A.P.; Glazunova, G.A.; Taranina, T.S.; Koltakova, S.I. 1988: Effect of heparin on fibrinogen formation during experimental toxic syndrome of disseminated intravascular coagulation Ukrainskii Biokhimicheskii Zhurnal 60(1): 23-29
Kurihara, I.; Yamaguchi, Y.; Soma, J.; Sato, H.; Ito, S.; Saito, T. 2000: Two aged patients with chronic renal failure and chronic disseminated intravascular coagulation secondary to aortic aneurysms: effect of continuous subcutaneous heparin infusion therapy Nihon Jinzo Gakkai Shi 42(7): 603-607
Scully, M.F.; Ellis, V.; Kakkar, V.V. 1986: Pentosan polysulphate: activation of heparin cofactor II or antithrombin III according to molecular weight fractionation Thrombosis Research 41(4): 489-499
Psuja, P. 1988: Effect of antithrombin IIi on the binding of heparin and its low molecular weight fraction CY 216 with endothelium in vitro Acta Haematologica Polonica 19(3-4): 143-149
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294